Agenus (AGEN) Long-Term Investments (2025 - 2026)

Agenus (AGEN) posted quarterly Long-Term Investments of $22.9 million for Q1 2026, down 5.56% quarter-over-quarter from $24.3 million in Q4 2025.

Analysis

Agenus (AGEN) Long-Term Investments (2025 - 2026) Analysis & Trends

Agenus' Long-Term Investments history runs 2 years deep, the most recent figure standing at $22.9 million for Q1 2026.

In Q1 2026, Long-Term Investments changed N/A year-over-year to $22.9 million; the TTM figure through Mar 2026 stood at $22.9 million (changed N/A YoY), while the FY2025 annual figure was $24.3 million, changed N/A from the prior year.
Long-Term Investments for Q1 2026 stood at $22.9 million, down from $24.3 million in the prior quarter.
The five-year high for Long-Term Investments was $30.5 million in Q3 2025, with the low at $22.9 million in Q1 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Vertex Pharmaceuticals	138.43 Bn	130.58 Bn	2.84 Bn	5.79 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	9.83 Bn
3	Argenx Se	63.34 Bn	58.15 Bn	1.37 Bn	-4.00 Mn
4	Moderna	57.98 Bn	52.85 Bn	52.00 Mn	1.77 Bn
5	Revolution Medicines	43.98 Bn	43.98 Bn	-	-
6	BeOne Medicines	39.92 Bn	34.82 Bn	1.53 Bn	-
7	Alnylam Pharmaceuticals	35.42 Bn	32.11 Bn	992.69 Mn	22.17 Mn
8	Royalty Pharma	28.42 Bn	27.58 Bn	-	372.10 Mn
9	Insmed	27.36 Bn	26.20 Bn	358.27 Mn	-
10	Agenus	341.87 Mn	341.87 Mn	34.52 Mn	25.45 Mn

Historic Data

Download Data